New sudan virus vaccine enters first human tests
NCT ID NCT07565090
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new vaccine designed to prevent Sudan virus disease, a severe illness similar to Ebola. About 112 healthy adults aged 18-50 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe and triggers the body's defenses against the virus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUDAN VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
-
George Washington University
RECRUITINGWashington D.C., District of Columbia, 20037, United States
-
Johnson County Clin-Trials
RECRUITINGLenexa, Kansas, 66219, United States